Sage — Metabolic Hypothesis of AREDS3
Milligram figures below are the amounts in the AREDS, AREDS2, and AREDS3 formulas, or amounts discussed in the essay, given as information — not a personal recommendation and not a regimen. Three statements about the original AREDS results were corrected against AREDS Report No. 8 (Archives of Ophthalmology, 2001): vitamins C and E were tested only alongside beta-carotene; only the full combination was significant across everyone enrolled; and self-reported anemia was slightly higher with zinc. A few other lines were edited for accuracy (the trial population, vitamin E in IU, which mechanisms come from cell and animal studies, and the tolerability of the lower zinc dose), and amount and timing lines are written as information, not instructions. Two clinical lines were also settled: where the essay discusses a lower-zinc option, zinc stays paired with copper, and without intermediate AMD the formula, zinc included, is not indicated. A caution for smokers and former smokers about beta-carotene formulas sits with the lutein and zeaxanthin history. The mouse zeaxanthin study is cited as Biswal et al., PLOS One 2018. The eye as a whole: Sage — Eye. The Dual Pathway week the strength timing refers to is explained on Sage — Strength. NAD+ routes: Sage — NAD precursors.
Metabolic Hypothesis of AREDS3
Disclaimer
This document presents a metabolic hypothesis integrating available clinical trial data from the Age-Related Eye Disease Studies (AREDS and AREDS2) with mechanistic biochemistry and the EnSurf framework of mitochondrial optimization. It is not medical advice, does not constitute a recommendation for or against any supplement, and is not a substitute for individualized clinical judgment. The original AREDS and AREDS2 trials established efficacy for the tested formulas in specific high-risk populations with intermediate age-related macular degeneration (AMD). AREDS3 is a commercial product formulation that has not been tested in a new randomized outcome trial. Individual responses vary. Consult a qualified physician before making changes to supplementation, particularly in the presence of diagnosed AMD or other medical conditions.
Framing: AMD as Dashboard of RPE Engine Failure
Intermediate-to-advanced age-related macular degeneration is viewed as a dashboard phenotype of chronic retinal pigment epithelium (RPE) and photoreceptor metabolic failure. The RPE faces extreme bioenergetic demand, relying on mitochondrial oxidative phosphorylation while continuously supporting photoreceptor outer-segment turnover. Cumulative insults—photo-oxidative stress, oxidized lipids, complement activation, and age-related declines in mitophagy and NAD+ recycling—produce mitochondrial dysfunction, lysosomal alkalinization, excess reactive oxygen species (ROS) beyond the hormetic range, and impaired clearance. The clinical features (drusen, geographic atrophy, neovascularization) are the visible readout of that engine-level failure. AREDS and AREDS2 demonstrated that a multi-component formula can slow progression in people who already express intermediate disease (or advanced AMD in one eye). AREDS3 retains core nutrients while lowering zinc and adding a B-vitamin complex. The sections below evaluate these elements against mitochondrial engine repair versus potential interference, and their fit within an EnSurf protocol of fuel quality, circadian alignment, and strength-derived ROS hormesis.
Lutein and Zeaxanthin: Macular and Mitochondrial Roles
Lutein (10 mg) and zeaxanthin (2 mg) replaced beta-carotene in AREDS2. Smokers and former smokers should avoid beta-carotene formulas (AREDS2 found more lung cancers in former smokers taking beta-carotene); AREDS2 and AREDS3 do not contain it. These xanthophyll carotenoids selectively accumulate in the macula as macular pigment optical density (MPOD). They filter short-wavelength blue light (400–500 nm), which reduces photo-oxidative generation of ROS in the outer retina and RPE. Beyond optical filtering, in cell and animal studies they act as chain-breaking antioxidants within lipid membranes, reduce phospholipid peroxidation, and limit A2E-mediated lipofuscin phototoxicity. In RPE cell models, lutein and zeaxanthin attenuate blue-light-induced proteasome inactivation and inflammatory gene shifts. In a mouse model of RPE-specific mitochondrial oxidative stress (Sod2 deletion), daily zeaxanthin supplementation preserved RPE structure, supported more intact mitochondria and compact basal infoldings, improved c-wave ERG amplitude (an RPE functional measure), and upregulated antioxidant genes (catalase, Hmox1, Nqo1) (Biswal et al., PLOS One 2018). These findings indicate that lutein and zeaxanthin support mitochondrial integrity and RPE resilience under oxidative load, consistent with an engine-level contribution to macular homeostasis rather than a purely optical effect.
NAD+ Pathways: Preiss-Handler, Salvage, and Recycling
NAD+ is central to mitochondrial function, sirtuin activity, DNA repair, and redox balance. Two primary routes supply it from vitamin B3 vitamers.
Preiss-Handler Pathway (Nicotinic Acid)
Nicotinic acid (NA) is converted by nicotinic acid phosphoribosyltransferase (NAPRT) to nicotinic acid mononucleotide (NaMN), then to nicotinic acid adenine dinucleotide (NaAD), and finally to NAD+ by NAD+ synthase. This pathway operates independently of the rate-limiting enzyme NAMPT and does not generate nicotinamide as an intermediate that inhibits sirtuins. Low-dose NA therefore elevates the NAD+ pool with minimal risk of sirtuin suppression. At the nutritional amounts discussed here as information (approximately 15–35 mg), flushing is uncommon with immediate-release forms; higher amounts trigger prostaglandin-mediated vasodilation. In dermal and other cells, NA can be particularly effective at raising NAD+ where NAPRT is expressed.
Salvage Pathway and Recycling (Nicotinamide)
Nicotinamide (NAM) is recycled through the salvage pathway: NAM is converted by nicotinamide phosphoribosyltransferase (NAMPT) to nicotinamide mononucleotide (NMN), then by NMNAT enzymes to NAD+. NAD+ consumers (sirtuins, PARPs, CD38) release NAM, which is re-captured by NAMPT, creating a recycling loop. NAM also acts as a competitive inhibitor of sirtuins via base-exchange at higher concentrations. The 32 mg NAM in AREDS3 is modest relative to doses shown to suppress sirtuin activity in vitro, but it is not zero. In an EnSurf context the hypothesis favors the Preiss-Handler route (low-dose NA) for NAD+ support, which avoids NAM-mediated sirtuin feedback. Adding NR or NMN on top of optimized EnSurf fuel/circadian/strength inputs plus low-dose NA and the modest NAM already present is unlikely to yield further meaningful engine-level gain; the salvage pathway is already fed by endogenous recycling, and any additional NAM byproduct risks incremental sirtuin interference.
Antioxidants and ROS Hormesis Interference
The antioxidant package in AREDS formulas (500 mg vitamin C and approximately 180 mg (400 IU) synthetic dl-α-tocopheryl acetate) was never tested without beta-carotene; AREDS tested vitamins C and E only as part of an antioxidant arm that also contained beta-carotene. Antioxidants alone produced a weaker, often non-significant reduction in progression compared with zinc or the full combination. High-dose exogenous vitamin C and E can scavenge contraction-induced ROS that serve as signals for PGC-1α-driven mitochondrial biogenesis, Nrf2 activation of endogenous antioxidant enzymes, and p38/ERK/p70S6K signaling linked to hypertrophic remodeling. In an EnSurf protocol that uses early-phase strength training to generate these hormetic pulses, the antioxidant load is the component most likely to work against the intended adaptation. Synthetic vitamin E is less efficiently retained by hepatic α-tocopherol transfer protein than natural RRR-α-tocopherol, so a larger fraction of the dose is not the preferred stereoisomer. Timing is discussed as a possible mitigation: vitamin C absorption peaks at 2–3 hours, so intake that falls after a strength session, rather than before it, would place the bulk of absorption after the main ROS signaling window. A smaller intake would also lower peak concentrations. Even so, chronic elevation of tissue vitamin E can still dampen baseline redox tone. On a fully optimized EnSurf base the antioxidant elements are the least aligned with engine repair.
Zinc Mechanisms
Zinc in AMD / RPE Support
Zinc was the stronger single component in the original AREDS factorial design, though only the full combination was significant across everyone enrolled. It is concentrated in the RPE/choroid and functions as a cofactor for Cu/Zn-superoxide dismutase, catalase, and glutathione peroxidase; supports glutathione synthesis; and can activate Nrf2. In cell and animal studies, it helps maintain lysosomal acidification required for photoreceptor outer-segment degradation and A2E clearance, preserves mitochondrial ATP production under oxidative load, and modulates complement. These actions address core RPE engine failures rather than acting as free-radical scavengers. The reduction from 80 mg to 25 mg in AREDS3 is supported by the AREDS2 secondary randomization, which found no significant difference in progression between the two doses, and is better tolerated.
Copper in the Formula
Copper (2 mg as cupric oxide) is included in AREDS formulas specifically to prevent zinc-induced copper deficiency. High-dose zinc competes with copper for intestinal absorption and induces metallothionein, which preferentially sequesters copper. Prolonged high zinc intake can therefore produce copper deficiency, with potential consequences including anemia and neurological effects. The copper is not present for a primary ocular mechanism; it is a countermeasure to maintain copper balance when zinc is supplemented at the tested doses. In the original trials, lab measures showed no copper deficiency anemia with the combination, though self-reported anemia was slightly higher with zinc.
Antimicrobial Mechanisms
Zinc is essential for microbes at low concentrations yet toxic in excess. Hosts exploit this through nutritional immunity: macrophages and neutrophils raise free Zn2+ inside phagolysosomes to intoxicate engulfed bacteria. Excess zinc causes mismetallation—it outcompetes other metals (especially Mn2+ and Fe2+) for binding sites on enzymes, inactivating them. In Streptococcus pneumoniae, high Zn2+ binds the Mn2+ uptake protein PsaA more tightly than manganese, starving the cell of Mn2+ and increasing oxidative-stress sensitivity. Additional effects include membrane disruption, interference with respiratory-chain enzymes (generating ROS), and inhibition of virulence factors. Zinc ionophores amplify these effects by raising intracellular free zinc beyond passive uptake.
Anticancer Mechanisms
Zinc’s effects on cancer cells are biphasic and cell-type dependent. At physiologic levels zinc often supports proliferation and can inhibit certain caspases. At higher local concentrations, free Zn2+ can trigger apoptosis via mitochondrial apoptogenesis (promoting Bax pore formation, cytochrome-c release, and caspase activation), ROS generation (impairing electron transport or activating NADPH oxidases), and p53-dependent pathways. Zinc ionophores raise intracellular free zinc preferentially in some transformed cells, tipping them into apoptosis or ferroptosis while sparing normal cells at the same dose. Additional reported effects include disruption of citrate metabolism in prostate cancer models. The core principle is elevation of free Zn2+ beyond the cell’s buffering and transporter capacity, producing toxicity through mismetallation, redox imbalance, and organelle dysfunction.
Timing Relative to Strength Hormesis
ROS signaling from a resistance session peaks during and in the hours immediately after the bout. Separating the antioxidant load from that window reduces interference. In the hypothesis, intake that falls after the main contraction-induced ROS signaling window has passed would interfere less than intake during it. When intermediate AMD is already present, whether and how to use this belongs with the treating eye doctor. It does not eliminate all risk of chronic redox dampening.
Integration and Overall Fit Within EnSurf
AREDS3 is a disease-stage intervention tested in a population already expressing the intermediate-AMD dashboard (or advanced AMD in one eye). Its zinc component maps reasonably onto RPE engine support (antioxidant enzymes, lysosomal function, mitochondrial resilience). Lutein and zeaxanthin contribute to macular pigment density, blue-light filtering, and RPE mitochondrial protection under oxidative stress. The modest NAM and other B vitamins provide limited NAD+ and one-carbon support but introduce a small sirtuin-inhibitory liability that is better minimized by relying on Preiss-Handler NA. The high-dose synthetic antioxidants are the least compatible element: they were not shown to be independently effective, and they can interfere with the ROS hormesis that strength training is intended to supply. Temporal separation and dose reduction reduce but do not eliminate that interference. Copper is present solely to offset zinc-related copper depletion risk.
For an individual on a full EnSurf protocol without established intermediate AMD, the formula adds little engine-level benefit and risks blunting adaptive signals; the formula isn't indicated without intermediate AMD, zinc included, and the cleaner approach is to rely on fuel, circadian, and strength inputs that generate endogenous NAD+ recycling, mitophagy, and controlled redox tone. For someone who already has intermediate disease, the hypothesis frames a lower-zinc AREDS3 (or zinc with copper) as a trade-off: it keeps the component with the strongest single-component trial signal, while separation from strength sessions would lessen antagonism of the hormetic inputs that EnSurf uses to address the same upstream mitochondrial failures. That choice belongs with the treating eye doctor. In both cases the primary engine repair remains the lifestyle protocol; AREDS3 is, at best, a secondary, stage-specific adjunct whose antioxidant fraction is the element most likely to work against rather than with that protocol.
Summary
Zinc remains the element of AREDS3 most consistent with RPE mitochondrial and lysosomal engine support; copper is included only to prevent zinc-induced copper deficiency. Lutein and zeaxanthin support macular pigment, blue-light filtration, and RPE mitochondrial resilience under oxidative stress. NAD+ support is better achieved via low-dose nicotinic acid through the Preiss-Handler pathway than through additional salvage-pathway precursors that generate inhibitory NAM. High-dose synthetic antioxidants sit outside the EnSurf logic of controlled ROS hormesis; in the hypothesis, their interference is smaller when intake is lower or separated from strength sessions. The overall hypothesis prioritizes upstream metabolic optimization over high-dose exogenous antioxidant supplementation once the EnSurf engine is running.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.
Related: Eye · NAD precursors (Kit) · PQQ (Kit) · Acetyl-L-carnitine (Kit; see its retina and optic-nerve passage) · Strength (Dual Pathway week) · Coach — AREDS3 · Surfer — Kit
See the notice at the top of this page. Working hypothesis, not medical advice and not a dosing recommendation. Consult a qualified physician before making changes to supplementation, particularly in the presence of diagnosed AMD or other medical conditions.